1. Home
  2. NRG vs UTHR Comparison

NRG vs UTHR Comparison

Compare NRG & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NRG Energy Inc.

NRG

NRG Energy Inc.

HOLD

Current Price

$161.43

Market Cap

32.0B

Sector

Utilities

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$493.41

Market Cap

20.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NRG
UTHR
Founded
1989
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Electric Utilities: Central
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
32.0B
20.3B
IPO Year
2000
1999

Fundamental Metrics

Financial Performance
Metric
NRG
UTHR
Price
$161.43
$493.41
Analyst Decision
Strong Buy
Buy
Analyst Count
14
12
Target Price
$188.86
$495.08
AVG Volume (30 Days)
1.7M
411.6K
Earning Date
11-06-2025
10-29-2025
Dividend Yield
1.09%
N/A
EPS Growth
62.56
16.08
EPS
6.78
26.38
Revenue
$29,779,000,000.00
$3,128,400,000.00
Revenue This Year
$7.41
$13.64
Revenue Next Year
$16.16
$5.78
P/E Ratio
$23.83
$18.73
Revenue Growth
5.91
13.50
52 Week Low
$79.57
$266.98
52 Week High
$180.54
$496.73

Technical Indicators

Market Signals
Indicator
NRG
UTHR
Relative Strength Index (RSI) 44.52 65.89
Support Level $163.25 $474.59
Resistance Level $171.57 $489.99
Average True Range (ATR) 6.32 10.16
MACD -0.04 -0.69
Stochastic Oscillator 18.02 91.64

Price Performance

Historical Comparison
NRG
UTHR

About NRG NRG Energy Inc.

NRG Energy is one of the largest retail energy providers in the US, with 6 million customers. Vivint Smart Home, which NRG acquired in 2023, has 2 million home-services customers. NRG also is one of the largest US independent power producers, with 13 gigawatts of coal, gas, and oil power generation capacity primarily in Texas. The LS Power asset acquisition will add 13 GW of gas-fired power plants mostly in the Eastern US. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: